awmsg logo

infliximab (Remicade®)

Reference No. 931

Publication date:

Appraisal information

infliximab (Remicade®) 100 mg powder for concentrate for solution for infusion

Company: Merck Sharp & Dohme Ltd
BNF category: Gastro-intestinal system
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
Submission Type: Nonsubmission
Status: Superseded
Advice No: Not available
Ratification by Welsh Government: 23/07/2012

Current Progress

Ratification by
Welsh Government

AWMSG advice

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA329) NICE GUIDANCE ISSUED FEBRUARY 2015 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology). In the absence of a submission from the holder of the marketing authorisation, infliximab (Remicade®) cannot be endorsed for use within NHS Wales for the treatment of severely active ulcerative colitis, in children and adolescents aged 6 to 17 years, who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.
Statement of Advice (SOA)